Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukaemia

Scand J Haematol. 1985 Mar;34(3):261-3. doi: 10.1111/j.1600-0609.1985.tb02789.x.

Abstract

Complete remissions were obtained with low dose cytosine arabinoside (ARA-C) in 8 of 21 previously untreated patients with ANLL above 60 years of age and in 2 of 4 previously treated patients below 60 years of age. 7 of the patients remain in remission after 1-26 months. The results demonstrate that low dose ARA-C with rather low toxicity may induce remissions in elderly patients with ANLL.

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Cytarabine / administration & dosage
  • Cytarabine / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Leukemia / drug therapy*
  • Male
  • Middle Aged

Substances

  • Cytarabine